Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Wagner

Showing results (281-290 of 355) with videos related to

Pageof 36
Sort By:
Voprosy Onkologii|April 23, 2013
[Optimization of treatment methods of surgical complications in lung cancer]A I Arsen'ev, A O Nefedov, E V Levchenko, et al.
Breast Cancer Research and Treatment|February 19, 2018
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)Lynne I Wagner, Fengmin Zhao, Paul E Goss, et al.
Blood Cancer Journal|April 2, 2022
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patientsSamilia Obeng-Gyasi, Noah Graham, Shaji Kumar, et al.
British Journal of Haematology|March 13, 2016
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402Michael E Williams, Fangxin Hong, Randy D Gascoyne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402Brad S Kahl, Fangxin Hong, Michael E Williams, et al.
Cancer Medicine|August 30, 2020
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trialLaurie E Steffen McLouth, Fengmin Zhao, Taofeek K Owonikoko, et al.
Practical Radiation Oncology|November 20, 2023
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM RegistryLeslie Ballas, Sikander Ailawadhi, Mohit Narang, et al.
Cancer Medicine|March 25, 2026
Qualitative Study of Breast Cancer and Lymphoma Patients Participating in a Physical Activity Intervention: The Case for Tailored Physical ActivityBrianna N Leitzelar, Juliana V Costa, Aylin A Aguilar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2019
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple MyelomaSagar Lonial, Susanna Jacobus, Rafael Fonseca, et al.
Cancer|October 22, 2025
Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatmentsJohn Devin Peipert, Shaili Ganatra, Fengmin Zhao, et al.
Pageof 36

Showing results (281-290 of 355) with videos related to

Sort By:
Pageof 36
Voprosy Onkologii|April 23, 2013
[Optimization of treatment methods of surgical complications in lung cancer]A I Arsen'ev, A O Nefedov, E V Levchenko, et al.
Breast Cancer Research and Treatment|February 19, 2018
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)Lynne I Wagner, Fengmin Zhao, Paul E Goss, et al.
Blood Cancer Journal|April 2, 2022
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patientsSamilia Obeng-Gyasi, Noah Graham, Shaji Kumar, et al.
British Journal of Haematology|March 13, 2016
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402Michael E Williams, Fangxin Hong, Randy D Gascoyne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402Brad S Kahl, Fangxin Hong, Michael E Williams, et al.
Cancer Medicine|August 30, 2020
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trialLaurie E Steffen McLouth, Fengmin Zhao, Taofeek K Owonikoko, et al.
Practical Radiation Oncology|November 20, 2023
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM RegistryLeslie Ballas, Sikander Ailawadhi, Mohit Narang, et al.
Cancer Medicine|March 25, 2026
Qualitative Study of Breast Cancer and Lymphoma Patients Participating in a Physical Activity Intervention: The Case for Tailored Physical ActivityBrianna N Leitzelar, Juliana V Costa, Aylin A Aguilar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2019
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple MyelomaSagar Lonial, Susanna Jacobus, Rafael Fonseca, et al.
Cancer|October 22, 2025
Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatmentsJohn Devin Peipert, Shaili Ganatra, Fengmin Zhao, et al.
Pageof 36